(PRAX) Praxis Precision Medicines - Ratings and Ratios
Cns Therapies, Epilepsy Treatments
PRAX EPS (Earnings per Share)
PRAX Revenue
Description: PRAX Praxis Precision Medicines
Praxis Precision Medicines Inc (NASDAQ:PRAX) is a biotechnology company listed on the NASDAQ exchange, operating in the United States. The companys stock is categorized under the GICS Sub Industry of Biotechnology.
To evaluate the companys financial health, we can examine key performance indicators (KPIs) such as Market Capitalization, which stands at $990.84M USD. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, indicates that the company is not generating earnings. Return on Equity (RoE) is significantly negative at -60.07%, suggesting substantial losses relative to shareholder equity.
The quarterly tax provision is a critical aspect of the companys financial reporting, as it reflects the companys tax obligations or benefits. A thorough analysis of this provision can reveal insights into the companys financial performance, including the impact of tax credits, loss carryforwards, or other tax-related items.
Economic drivers for biotechnology companies like PRAX include the demand for innovative treatments, the success of their product pipeline, and the ability to secure funding for research and development. Key factors influencing the stocks performance include the companys progress in clinical trials, FDA approvals, and the competitive landscape within the biotechnology sector.
To assess the stocks potential, we must consider its volatility, as indicated by its Beta of 2.633, which is significantly higher than the market average, suggesting that the stocks price movements are more extreme than those of the broader market. Average trading volume is substantial, with 455,347 shares traded daily, indicating a relatively liquid market for the stock.
PRAX Stock Overview
| Market Cap in USD | 794m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-10-16 |
PRAX Stock Ratings
| Growth Rating | -33.9% |
| Fundamental | 23.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.6% |
| Analyst Rating | 4.42 of 5 |
PRAX Dividends
Currently no dividends paidPRAX Growth Ratios
| Growth Correlation 3m | -23.7% |
| Growth Correlation 12m | -55.9% |
| Growth Correlation 5y | -58% |
| CAGR 5y | 1.24% |
| CAGR/Max DD 3y | 0.01 |
| CAGR/Mean DD 3y | 0.03 |
| Sharpe Ratio 12m | 0.79 |
| Alpha | 0.19 |
| Beta | 0.206 |
| Volatility | 89.20% |
| Current Volume | 463.8k |
| Average Volume 20d | 311.3k |
| Stop Loss | 41.2 (-6.4%) |
| Signal | 0.59 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-251.0m TTM) > 0 and > 6% of Revenue (6% = 465.9k TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA -3.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3322 % (prev 19.0k%; Δ -15.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.42 (>3.0%) and CFO -191.3m > Net Income -251.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (21.5m) change vs 12m ago 14.08% (target <= -2.0% for YES) |
| Gross Margin 98.80% (prev 63.24%; Δ 35.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.74% (prev 0.40%; Δ 1.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -28.41
| (A) 0.57 = (Total Current Assets 306.6m - Total Current Liabilities 48.6m) / Total Assets 452.8m |
| (B) -2.16 = Retained Earnings (Balance) -977.2m / Total Assets 452.8m |
| warn (B) unusual magnitude: -2.16 — check mapping/units |
| (C) -0.60 = EBIT TTM -266.6m / Avg Total Assets 446.9m |
| (D) -20.09 = Book Value of Equity -976.8m / Total Liabilities 48.6m |
| Total Rating: -28.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.63
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -26.72% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.00 = -2.50 |
| 6. ROIC - WACC (= -70.58)% = -12.50 |
| 7. RoE -60.07% = -2.50 |
| 8. Rev. Trend 20.46% = 1.53 |
| 9. EPS Trend -78.02% = -3.90 |
What is the price of PRAX shares?
Over the past week, the price has changed by +9.45%, over one month by -5.58%, over three months by +1.31% and over the past year by -23.72%.
Is Praxis Precision Medicines a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRAX is around 37.15 USD . This means that PRAX is currently overvalued and has a potential downside of -15.63%.
Is PRAX a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PRAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 101.3 | 130.1% |
| Analysts Target Price | 101.3 | 130.1% |
| ValueRay Target Price | 40.8 | -7.4% |
Last update: 2025-09-16 04:39
PRAX Fundamental Data Overview
CCE Cash And Equivalents = 301.3m USD (Cash And Short Term Investments, last quarter)
P/S = 102.2119
P/B = 1.9635
Beta = 2.623
Revenue TTM = 7.76m USD
EBIT TTM = -266.6m USD
EBITDA TTM = -266.4m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 755.0k USD (from shortTermDebt, last quarter)
Debt = 755.0k USD (Calculated: Short Term 755.0k + Long Term 0.0)
Net Debt = -156.7m USD (from netDebt column, last quarter)
Enterprise Value = 493.2m USD (793.7m + Debt 755.0k - CCE 301.3m)
Interest Coverage Ratio = unknown (Ebit TTM -266.6m / Interest Expense TTM 0.0)
FCF Yield = -26.72% (FCF TTM -131.8m / Enterprise Value 493.2m)
FCF Margin = -1697 % (FCF TTM -131.8m / Revenue TTM 7.76m)
Net Margin = -3233 % (Net Income TTM -251.0m / Revenue TTM 7.76m)
Gross Margin = 98.80% ((Revenue TTM 7.76m - Cost of Revenue TTM 93.0k) / Revenue TTM)
Tobins Q-Ratio = -0.50 (set to none) (Enterprise Value 493.2m / Book Value Of Equity -976.8m)
Interest Expense / Debt = 14.04% (Interest Expense 106.0k / Debt 755.0k)
Taxrate = 21.0% (US default)
NOPAT = -266.6m (EBIT -266.6m, no tax applied on loss)
Current Ratio = 6.31 (Total Current Assets 306.6m / Total Current Liabilities 48.6m)
Debt / Equity = 0.00 (Debt 755.0k / last Quarter total Stockholder Equity 404.2m)
Debt / EBITDA = -0.00 (Net Debt -156.7m / EBITDA -266.4m)
Debt / FCF = -0.01 (Debt 755.0k / FCF TTM -131.8m)
Total Stockholder Equity = 417.9m (last 4 quarters mean)
RoA = -55.43% (Net Income -251.0m, Total Assets 452.8m )
RoE = -60.07% (Net Income TTM -251.0m / Total Stockholder Equity 417.9m)
RoCE = -63.81% (Ebit -266.6m / (Equity 417.9m + L.T.Debt 0.0))
RoIC = -63.81% (NOPAT -266.6m / Invested Capital 417.9m)
WACC = 6.77% (E(793.7m)/V(794.4m) * Re(6.77%)) + (D(755.0k)/V(794.4m) * Rd(14.04%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 19.41%
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -131.8m)
EPS Correlation: -78.02 | EPS CAGR: -58.82% | SUE: -0.10 | # QB: 0
Revenue Correlation: 20.46 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for PRAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle